Nom du produit:1-propylazetidin-3-ol
IUPAC Name:1-propylazetidin-3-ol
- CAS:1340301-52-1
- Formule moléculaire:C6H13NO
- Pureté:95%+
- Numéro de catalogue:CM746619
- Poids moléculaire:115.18
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:1340301-52-1
- Formule moléculaire:C6H13NO
- Point de fusion:-
- Code SMILES:CCCN1CC(O)C1
- Densité:
- Numéro de catalogue:CM746619
- Poids moléculaire:115.18
- Point d'ébullition:
- N° Mdl:MFCD18308893
- Stockage:
Category Infos
- Azetidines
- Azetidines are an important class of saturated four-membered nitrogen-containing heterocyclic compounds. The research hotspots related to this structure mainly focus on two aspects: one is the research of pharmaceutical chemistry; the other is related to chiral azetidines, using rigid azetidine compounds as chiral ligands for asymmetric catalytic reactions. Many nitrogen-containing heterocycles play important roles in drug structures, and in many cases small structural changes can improve ligand selectivity and pharmacokinetic properties.
- Where to buy Azetidines
- Where to buy ADC-Cytotoxins? Chemenu Provide Azetidines with high quality and competitive price. Contact us Now.
Column Infos
- Palazestrant
- Olema Oncology is advancing the development of Palazestrant (OP-1250) in metastatic breast cancer in 2024. Palazestrant is an oral complete ER antagonist (CERAN) and selective ER degrader (SERD). It potently binds and completely blocks transcriptional activity of both wild-type and ESR1-mutant ER with favorable tolerability and anti-tumor activity.
Palazestrant is under clinical development both in combination with Novartis' CDK4/6 inhibitor Kisqali (Ribociclib) as a first-line therapy for advanced estrogen receptor-positive, HER2-negative breast cancer, and as a monotherapy compared to standard of care treatment in second- and third-line advanced or metastatic ER-positive, HER2-negative breast cancer.